NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Ascending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68788-8481-03 | 68788-8481 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8481-06 | 68788-8481 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8481-09 | 68788-8481 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8484-01 | 68788-8484 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8484-03 | 68788-8484 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8484-06 | 68788-8484 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68788-8484-09 | 68788-8484 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | July 13, 2023 | In Use | ||
68071-3494-03 | 68071-3494 | Tamoxifen Citrate | Tamoxifen Citrate | 10.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Aug. 28, 2023 | In Use | ||
68083-0515-01 | 68083-0515 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 13, 2023 | In Use | ||
68083-0516-01 | 68083-0516 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 13, 2023 | In Use | ||
68083-0517-10 | 68083-0517 | Octreotide Acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 22, 2023 | In Use | ||
68083-0560-10 | 68083-0560 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | June 22, 2023 | In Use | ||
70518-2369-00 | 70518-2369 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct. 19, 2019 | In Use | ||
70518-2369-02 | 70518-2369 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | May 25, 2023 | In Use | ||
70518-3818-00 | 70518-3818 | ESTRADIOL | ESTRADIOL | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Aug. 3, 2023 | In Use | ||
70954-0565-10 | 70954-0565 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 6, 2023 | In Use | ||
70954-0565-20 | 70954-0565 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 6, 2023 | In Use | ||
70954-0566-10 | 70954-0566 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 6, 2023 | In Use | ||
70954-0566-20 | 70954-0566 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 6, 2023 | In Use | ||
70954-0564-10 | 70954-0564 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Sept. 6, 2023 | In Use | ||
42291-0374-90 | 42291-0374 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan. 5, 2015 | In Use | ||
42291-0374-30 | 42291-0374 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan. 4, 2024 | In Use | ||
51655-0520-52 | 51655-0520 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | Dec. 27, 2023 | In Use | ||
55150-0336-01 | 55150-0336 | TESTOSTERONE ENANTHATE | TESTOSTERONE ENANTHATE | 200.0 mg/mL | Hormonal Therapy | Androgen | Intramuscular | Feb. 28, 2024 | In Use | ||
70518-3913-00 | 70518-3913 | Medroxyprogesterone acetate | Medroxyprogesterone acetate | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | Nov. 10, 2023 | In Use | ||
72162-2208-06 | 72162-2208 | Tamoxifen Citrate | Tamoxifen Citrate | 10.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 5, 2024 | In Use | ||
72162-2209-03 | 72162-2209 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan. 5, 2024 | In Use | ||
82868-0026-30 | 82868-0026 | Estradiol | Estradiol | 2.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Nov. 9, 2023 | In Use | ||
82868-0038-30 | 82868-0038 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb. 5, 2024 | In Use | ||
82868-0038-90 | 82868-0038 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Jan. 18, 2024 | In Use | ||
83634-0203-74 | 83634-0203 | Fulvestrant | Fulvestrant | 50.0 mg/mL | Hormonal Therapy | Estrogen Receptor Antagonist | Intramuscular | Feb. 28, 2024 | In Use | ||
57377-0025-01 | 57377-0025 | Estradiol pellet | Estra-25 | 25.0 mg/1 | Hormonal Therapy | Estrogen | Subcutaneous | Jan. 1, 2017 | In Use | ||
57377-0050-01 | 57377-0050 | Estradiol pellet | Estra-50 | 50.0 mg/1 | Hormonal Therapy | Estrogen | Subcutaneous | Jan. 1, 2017 | In Use | ||
68001-0610-25 | 68001-0610 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Feb. 28, 2024 | In Use | ||
76075-0101-01 | 76075-0101 | Carfilzomib | Kyprolis | 60.0 mg/30mL | Chemotherapy | Proteasome Inhibitor | 20S | Intravenous | July 20, 2012 | In Use | |
76075-0102-01 | 76075-0102 | Carfilzomib | Kyprolis | 30.0 mg/15mL | Chemotherapy | Proteasome Inhibitor | 20S | Intravenous | July 15, 2016 | In Use | |
76075-0103-01 | 76075-0103 | carfilzomib | KYPROLIS | 10.0 mg/5mL | Chemotherapy | Proteasome Inhibitor | 20S | Intravenous | May 23, 2018 | In Use | |
63020-0078-01 | 63020-0078 | Ixazomib | Ninlaro | 2.3 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | No Longer Used | |
63020-0078-02 | 63020-0078 | Ixazomib | Ninlaro | 2.3 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | Oct. 31, 2023 | No Longer Used |
63020-0079-01 | 63020-0079 | Ixazomib | Ninlaro | 3.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | No Longer Used | |
63020-0079-02 | 63020-0079 | Ixazomib | Ninlaro | 3.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | Oct. 31, 2023 | No Longer Used |
63020-0080-01 | 63020-0080 | Ixazomib | Ninlaro | 4.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | Oct. 31, 2023 | No Longer Used |
63020-0080-02 | 63020-0080 | Ixazomib | Ninlaro | 4.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 20S | Oral | Nov. 20, 2015 | Oct. 31, 2023 | No Longer Used |
63020-0049-01 | 63020-0049 | Bortezomib | Velcade | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 13, 2003 | In Use | |
00409-1703-01 | 00409-1703 | BORTEZOMIB | BORTEZOMIB | 2.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 16, 2022 | In Use | |
00409-1704-01 | 00409-1704 | BORTEZOMIB | BORTEZOMIB | 1.0 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 16, 2022 | In Use | |
10019-0991-01 | 10019-0991 | Bortezomib | BORTEZOMIB | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use | |
25021-0244-10 | 25021-0244 | BORTEZOMIB | BORTEZOMIB | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 1, 2022 | In Use | |
50742-0484-01 | 50742-0484 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 1, 2022 | In Use | |
51817-0586-01 | 51817-0586 | Bortezomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | May 2, 2022 | In Use |
Found 10,000 results in 7 milliseconds — Export these results